Abstract: A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body. The amount of WS12 releasably adhered to the polymeric lens body provides a basal tear concentration in lens wearers of 2 ?g/ml to 8 ?g/ml WS12 after 30 minutes of lens wear. The WS12-releasing contact lens can be used to increase contact lens comfort, reduce eye fatigue, reduce sensations of ocular dryness and impart a pleasant, cooling sensation in the lens wearer without causing stinging or burning upon insertion.

Abstract: A WS12-releasing contact lens is described as well as method of manufacturing the same. The WS12-releasing contact lens comprises a polymeric lens body and WS12 releasably adhered to the polymeric lens body. The amount of WS12 releasably adhered to the polymeric lens body provides a basal tear concentration in lens wearers of 2 ?g/ml to 8 ?g/ml WS12 after 30 minutes of lens wear. The WS12-releasing contact lens can be used to increase contact lens comfort, reduce eye fatigue, reduce sensations of ocular dryness and impart a pleasant, cooling sensation in the lens wearer without causing stinging or burning upon insertion.

Abstract: A contact lens having an amount of at least one cooling agent and at least one TRPV1 inhibitor releasably adhered is described as well as method of manufacturing the same. The contact lens can be comfortably worn by contact lens wearers and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer and further can reduce or avoid any stinging/burning sensation when the contact lens is first used or a short time thereafter.

Abstract: A contact lens having an amount of at least one cooling agent and at least one TRPV1 inhibitor releasably adhered is described as well as method of manufacturing the same. The contact lens can be comfortably worn by contact lens wearers and can increase the duration of comfortable lens wearing time and/or reduce lens awareness events and/or reduce contact lens dryness in a symptomatic contact lens wearer and further can reduce or avoid any stinging/burning sensation when the contact lens is first used or a short time thereafter.

Abstract: Methods and compositions for the prophylactic and therapeutic treatment of retinal disorders associated with neovascularization using topical ophthalmic compositions comprising hydroxamic acid matrix metalloproteinase inhibitors such as batimastat.

Abstract: A topical otic composition containing an azalide antibiotic. A topical otic composition containing an azalide antibiotic and an medicament. A topical otic composition containing an azalide antibiotic and a polymer suspending agent. And methods for treating or preventing infections in the ear using azalide antibiotic compositions.

Abstract: Promoter sequences of the optineurin gene can be used to diagnose, prognose, and treat glaucoma and related disorders. Methods, kits, and nucleic acids capable of detecting or containing polymorphisms located within the promoter region of the optineurin gene are also provided. The promoter sequences can also be used to generate cells, vectors, and nucleic acids useful in a variety of diagnostic and prognostic methods and kits as well as therapeutic compounds, compositions and methods.